Reference is made to to the stock exchange notice by Aqua Bio Technology ASA (" ABT " or the " Company ") published on 4 December 2018 regarding a private placement with gross proceeds of NOK 11.735 million (the " Private Placement ") and a repair issue following the Private Placement (the " Subsequent Offering "). The investors in the Private Placement received one (1) independent subscription right (a " Warrant ") per share applied for and allocated in the Private Placement, and each Warrant gives the investor the right to subscribe for one (1) additional share in the Company for NOK 2.50 per share. The Company issued 4,694,000 Warrants to the investors in the Private Placement.

Each person who subscribes for and are allocated shares in the Subsequent Offering will receive one (1) Warrant per share actually subscribed for and allocated in the Subsequent Offering.

Reference is further made to the general meeting's resolution on 7 January 2019 to issue Warrants in the Private Placement and the Subsequent Offering, and to the prospectus published by the Company on 14 February 2019 (the " Prospectus ").

The Company has applied for, and Oslo Børs has granted, listing of the Warrants on Oslo Axess. The Warrants hold ISIN NO 001 0841901. The Warrants issued in the Private Placement will be listed as of today under ticker "ABT S". The Warrants to be issued in the Subsequent Offering will be listed following the expiry of the subscription period in the Subsequent Offering, expected on or about 12 March 2019.

The Warrants will be tradable on the Oslo Axess in the period from 14 February 2019 to and including 30 August 2019. The Warrants may be transferred freely.

The Warrants may be exercised by each holder in the period from 30 June 2019 to and including 1 September 2019 by written notice to the Company, on the following address:

Aqua Bio Technology ASA Fornebuveien 37 1366 Lysaker Norway E-mail: arvid@aquabiotech.no

Investors who require issuance of shares through exercise of Warrants shall receive these as effectively as practically possible after 1 August 2019 (for investors who have exercised Warrants prior to 31 July 2019) or after 1 September 2019 (for investors who have exercised their Warrants within the end of 1 September 2019). The Company will provide payment information for share deposits following exercise of Warrants.

Warrants that are not exercised within the end of 1 September 2019 will lapse automatically without compensation to the holder.

The Warrants will have economic value if the market price of the Company's shares is higher than the strike price of each Warrant, i.e. NOK 2.50, at the time that new shares are issued to holders of Warrants.

Information about the Warrants is also available in the Prospectus, which can be found at www.aquabiotechnology.com .

For further information, please call Arvid Lindberg, Head of sales and marketing, telephone +47 9824 5410 or arvid@aquabiotech.no.

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on the Axess market of the Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.